Meeting
2023 ASCO Annual Meeting
Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361.
Authors
Ozgur Ozyilkan
Adana Baskent Üniversitesi, Adana, Turkey
Ozgur Ozyilkan , Raymond S. McDermott , María José Juan-Fita , Andrey Semenov , Boris Alekseev , Raanan Berger , Woo Kyun Bae , Pongwut Danchaivijitr , Jianxin Lin , Abhishek Amar Bavle , Kentaro Imai , Cagatay Arslan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02853305
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4513)
DOI
10.1200/JCO.2023.41.16_suppl.4513
Abstract #
4513
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
First Author: Benjamin Miron
Poster
2024 ASCO Genitourinary Cancers Symposium
Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
First Author: Inkeun Park
Poster
2022 ASCO Genitourinary Cancers Symposium
Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.
First Author: Thomas Powles
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar